Lycia Therapeutics
Oncology Therapeutics · Drug Discovery
2open roles
50+people
2025founded
19stories in the press
Overview
Lycia Therapeutics is a clinical-stage biotechnology company that uses extracellular protein degradation to eliminate the source of disease. It hires medical directors and senior development leaders for clinical development, clinical pharmacology and nonclinical work. The company is headquartered in South San Francisco, California, United States.
Jobs
$125k – $150k per year · Remote (United States) · Full-Time · 2+ years exp · Bachelor's Degree · South San Francisco
GCP
Life Sciences
Good Clinical Practice
MedTech
CAPA
Apply
$175k – $202k per year · Remote (United States) · Full-Time · 7+ years exp · PhD · South San Francisco
Good Clinical Practice
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$176k
Typical range
$143k – $420k
Open positions
4
4
Jobs
Junior
25%
Senior
75%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 1 | $150k | $150k |
| Senior | 3 | $202k | $143k – $420k |
Highest paying role
Vice President (VP) / Senior VP, Clinical Development
$420k
Normalized to USD per year
Visa sponsorship
1
H-1B filings in 12 months
1
Green card filings
$95k
Median offered salary
Who they sponsor
Other biological scientists
1
In the register as Lycia Therapeutics, Inc., South San Francisco, CA (+1 more)
Other sponsors in the same field
Genentech 
Exelixis 
Nurix Therapeutics
See 4 open roles Alert me
US Department of Labor · latest filing Apr 23, 2026 · Visa details by country
Growth
Hiring Momentum
21/100
Hiring freeze
Open positions
4
0 opened / 0 closed in 30 days
Median time-to-fill
219 days
faster than 5% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Administrative
50% ▲
Biotech
50% ▲
People
Aetna Wun Trombley
Executive Officer, Director
Amy Bachrodt
Executive Officer
Jeremy Caldwell
Executive Officer, Director
Tim Anderson
Director
William Rieflin
Director
Clare Ozawa
Director
Laurent Fischer
Director
Ming Fang
Director
Thomas Woiwode
Director
Andrew Gottesdiener
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Lycia Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
5
Postings analysed
5
Stack modernity
51/100
Cloud & platforms
GCP
Practices & domains
Good Clinical Practice
CAPA
GLP
GMP
Sign in to see how your skills match this stack
Sign In
News
Lycia Therapeutics (LYCA) raises $317.5 million in one of biotech
Lycia Therapeutics priced at $18 a share, pulling in $317.5 million on 17.64 million shares, one of the larger biotech raises to clear this year. Jefferies, TD Cowen, Evercore ISI and Guggenheim led…
Read more
Report
Lycia Therapeutics Soars 47% in Nasdaq Debut on
Key TakeawaysLycia Therapeutics shares jumped 47% in their Nasdaq debut after the company raised $317. 5 million in an upsized IPO priced at $18 a share.
Read more
Report
Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (
Read more
Report
Allergy Disease R&D Company Lycia Therapeutics Expands Fundraising Scale and Is Set to List on Nasdaq
Read more
Report
Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
The post Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering appeared first on Lycia Therapeutics.
Read more
Report
Allergy and autoimmune biotech Lycia Therapeutics sets terms for $250 million IPO
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, announced terms for its IPO on Tuesday.The South San Francisco, CA-based company plans to raise $250 million by offering 14.7 million shares at a pric
Read more
Report
Lycia Therapeutics, launched around Nobel Prize winner's work, could raise more than $300 million in IPO
Read more
Report
Lycia Therapeutics sets IPO terms with a $250 million target
Lycia Therapeutics just put numbers on its Nasdaq debut: 14.7 million shares at $16 to $18, or about $250 million at the top. Jefferies, TD Cowen and Evercore ISI are leading, and pricing is the next…
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
South San Francisco
South San Francisco
United States
HQ
4 open roles 2 posted in 90 days 50% remote 50-200 est. staff $229k Avg Salary
hires for Biotech, Administrative, Sales